# OnCo record paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016" ;
  schema:name "CIMAvax-EGF as switch maintenance in advanced non-small cell lung cancer: the Cuban phase III trial"@en ;
  schema:description "In 405 Cuban patients with advanced lung cancer, the EGF vaccine CIMAvax-EGF after chemotherapy gave a median survival of 10.8 months against 8.9 with supportive care; the difference was significant only by a weighted test and among patients who had at least four doses."@en ;
  schema:url <https://onco.cc/key-papers/paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.CCR-15-0855>, <https://pubmed.ncbi.nlm.nih.gov/26927662/> ;
  schema:sameAs <https://doi.org/10.1158/1078-0432.CCR-15-0855> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Rodriguez PC, Popa X, Martínez O, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/cimavax-egf/> ;
  onco:companies <https://onco.cc/companies/cimab/> ;
  onco:institutions <https://onco.cc/institutions/inor-cuba/> .
